Dempze Nancy E Reduces Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Dempze Nancy E cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 23.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,368 shares of the biopharmaceutical company’s stock after selling 2,502 shares during the period. Dempze Nancy E’s holdings in Gilead Sciences were worth $592,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of GILD. Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of Gilead Sciences by 583.3% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 1,400 shares during the period. Dubuque Bank & Trust Co. raised its stake in shares of Gilead Sciences by 19.4% in the 1st quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 267 shares during the period. Penserra Capital Management LLC raised its stake in shares of Gilead Sciences by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 144 shares during the period. Webster Bank N. A. raised its stake in shares of Gilead Sciences by 51.7% in the 1st quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 624 shares during the period. Finally, American Beacon Advisors Inc. acquired a new stake in shares of Gilead Sciences in the 1st quarter valued at about $143,000. Hedge funds and other institutional investors own 74.05% of the company’s stock.

Several analysts have issued reports on GILD shares. TheStreet raised Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Thursday, September 7th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $82.00 target price on shares of Gilead Sciences in a research report on Tuesday, July 4th. Vetr downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 target price on the stock. in a research report on Wednesday, June 21st. Deutsche Bank AG started coverage on Gilead Sciences in a research report on Friday, June 23rd. They issued a “buy” rating and a $79.00 target price on the stock. Finally, Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 target price on the stock in a research report on Monday, July 17th. Eleven investment analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $83.79.

In related news, CFO Robin L. Washington sold 51,820 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the transaction, the chief financial officer now owns 43,352 shares in the company, valued at $3,684,920. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the transaction, the insider now owns 3,199,969 shares in the company, valued at approximately $227,197,799. The disclosure for this sale can be found here. Insiders sold 466,819 shares of company stock worth $36,740,240 in the last 90 days. Corporate insiders own 1.30% of the company’s stock.

Gilead Sciences, Inc. (NASDAQ:GILD) traded up 0.33% during mid-day trading on Friday, reaching $82.56. The company had a trading volume of 6,020,436 shares. The firm has a market capitalization of $107.82 billion, a price-to-earnings ratio of 8.97 and a beta of 1.19. The firm has a 50-day moving average price of $76.95 and a 200 day moving average price of $70.12. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping analysts’ consensus estimates of $2.11 by $0.45. The company had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm’s revenue was down 8.2% compared to the same quarter last year. During the same quarter last year, the company earned $3.08 EPS. Analysts expect that Gilead Sciences, Inc. will post $8.75 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.53%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s payout ratio is 22.58%.

TRADEMARK VIOLATION NOTICE: This report was first published by BBNS and is the sole property of of BBNS. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://baseballnewssource.com/markets/gilead-sciences-inc-gild-stake-decreased-by-dempze-nancy-e/1603635.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Cleveland Indians Winning Streak Reaches 18
Cleveland Indians Winning Streak Reaches 18


Leave a Reply

 
© 2006-2017 BBNS.